Icon

ENTRESTO (nda207620)- (24MG;26MG,49MG;51MG,97MG;103MG)

SACUBITRIL; VALSARTAN NOVARTIS PHARMS CORP
24MG;26MG,49MG;51MG,97MG;103MG
Yes No
2036-May-09 2020-Jul-07
None None
None No
ENTRESTO is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.
9 0 2
Total Other Developers 34
Drugs with Suitability No
24MG;26MG ** ** Up - -
49MG;51MG ** ** Up - -
97MG;103MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** **** ******* *** *********** **** **. **, ** & **, ******* ****** ***** *********** *******, ******** ******, **********, ****** ******* ******, ***** (***) ***
****** ****** ****** **** ******* *********** **** **. **, ** & **, ******* ****** ***** *********** *******, ******** ******, **********, ****** ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.